CD52 and acute myeloid leukemia: To identify novel therapeutic targets in EVI1high AML, we analyzed gene expression profiles of EVI1high AML cells and identified GPR56, CD52 molecule (CD52), integrin α6 (ITGA6), and angiopoietin-1 (ANGPT1) as candidate targets for EVI1high AML12–14.